Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
J Interferon Cytokine Res ; 42(10): 542-549, 2022 10.
Article in English | MEDLINE | ID: covidwho-2284705

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic has affected the entire world, and has a variety of clinical presentations. The aim of this study is to determine the relationships of fecal cytokines and markers with the symptoms and prognosis of children with COVID-19 infection, and to identify noninvasive markers during follow-up. In a cohort of 40 COVID-19-positive children and 40 healthy controls, fecal cytokines and markers were examined in stool samples. A binary logistic model was used to assess the potential of cytokines as risk factors for hospitalization. Odds ratios (ORs) with 95% confidence intervals (CIs) were reported. A P-value <0.05 was accepted as statistically significant. Levels of fecal lysozyme, myeloperoxidase, hemoglobin, and interleukin-5 (IL-5) (P < 0.05) were significantly higher among the patients than controls. In a logistic regression analysis, fecal IL-2 (OR = 3.83; 95% CI: 1.44-15.92), IL-4 (OR = 2.96; 95% CI: 1.09-12.93), IL-5 (OR = 4.56; 95% CI: 1.18-27.88), IL-10 (OR = 2.71 95% CI: 1.19-7.94), interferon-gamma (IFN-γ) (OR = 4.03; 95% CI: 1.44-15.73), IFN-α (OR = 3.02; 95% CI: 1.08-11.65), calcium-binding protein B S100 (S100 B) (OR = 4.78; 95% CI: 1.31-27.82), neutrophil elastase (NE) 2 (OR = 4.07; 95% CI: 1.17-19.69), and matrix metalloproteinase 1 (MMP-1) (OR = 3.67; 95% CI: 1.1-18.82) levels were significantly higher in hospitalized patients with COVID-19 infection than outpatients. We demonstrated that various fecal cytokines and markers were increased in patients who had COVID-19. Fecal IL-2, IL-4, IL-5, IL-10, IFN-γ, IFN-α, S100 B, NE, and MMP-1 levels were significantly elevated in hospitalized patients. We suggest that the fecal and serum levels of cytokines could be used to predict the prognosis of COVID-19 disease, although more studies are needed to confirm this.


Subject(s)
COVID-19 , Cytokines , Child , Humans , Cytokines/metabolism , Interleukin-5/metabolism , Matrix Metalloproteinase 1/metabolism , Interleukin-10 , Leukocyte Elastase/metabolism , Peroxidase/metabolism , Muramidase/metabolism , Interferon-gamma , Interleukin-4 , Interleukin-2 , Biomarkers , Prognosis , Interferon-alpha/metabolism , Calcium-Binding Proteins
2.
Pediatr Pulmonol ; 57(1): 176-184, 2022 01.
Article in English | MEDLINE | ID: covidwho-1955933

ABSTRACT

BACKGROUND: Tracheostomy-related morbidity and mortality mainly occur due to decannulation, misplacement, or obstruction of the tube. A standardized training can improve the skills and confidence of the caregivers in tracheostomy care (TC). OBJECTIVE: Our primary aim was to evaluate the efficiency of standardized training program on the knowledge and skills (changing-suctioning the tracheostomy tube) of the participants regarding TC. MATERIALS AND METHODS: Sixty-five caregivers of children with tracheostomy were included. First, participants were evaluated with written test about TC and participated in the practical tests. Then, they were asked to participate in a standardized training session, including theoretical and practical parts. Baseline and postintervention assessments were compared through written and practical tests conducted on the same day. RESULTS: A significant improvement was observed in the written test score after the training. The median number of correct answers of the written test including 23 questions increased 26%, from 12 to 18 (p < .001). The median number of correct steps in tracheostomy tube change (from 9 to 16 correct steps out of 16 steps, 44% increase) and suctioning the tracheostomy tube (from 9 to 17 correct steps out of 18 steps, 44% increase) also improved significantly after the training (p < .001, for both). CONCLUSION: Theoretical courses and practical hands-on-training (HOT) courses are highly effective in improving the practices in TC. A standardized training program including HOT should be implemented before discharge from the hospital. Still there is a need to assess the impact of the program on tracheostomy-related complications, morbidity, and mortality in the long term.


Subject(s)
Caregivers , Tracheostomy , Child , Humans , Patient Discharge
3.
J Trop Pediatr ; 68(2)2022 02 03.
Article in English | MEDLINE | ID: covidwho-1702787

ABSTRACT

Predictors of early diagnosis and severe infection in children with coronavirus disease 2019 (COVID-19), which has killed more than 4 million people worldwide, have not been identified. However, some biomarkers, including cytokines and chemokines, are associated with the diagnosis, pathogenesis and severity of COVID-19 in adults. We examined whether such biomarkers can be used to predict the diagnosis and prognosis of COVID-19 in pediatric patients. Eighty-nine children were included in the study, comprising three patient groups of 69 patients (6 severe, 36 moderate and 27 mild) diagnosed with COVID-19 by real-time polymerase chain reaction observed for 2-216 months and clinical findings and 20 healthy children in the same age group. Hemogram, coagulation, inflammatory parameters and serum levels of 16 cytokines and chemokines were measured in blood samples and were analyzed and compared with clinical data. Interleukin 1-beta (IL-1ß), interleukin-12 (IL-12) and interferon gamma-induced protein 10 (IP-10) levels were significantly higher in the COVID-19 patients (p = 0.035, p = 0.006 and p < 0.001). Additionally, D-dimer and IP-10 levels were higher in the severe group (p = 0.043 for D-dimer, area under the curve = 0.743, p = 0.027 for IP-10). Lymphocytes, C-reactive protein and procalcitonin levels were not diagnostic or prognostic factors in pediatric patients (p = 0.304, p = 0.144 and p = 0.67). Increased IL-1ß, IL-12 and IP-10 levels in children with COVID-19 are indicators for early diagnosis, and D-dimer and IP-10 levels are predictive of disease severity. In children with COVID-19, these biomarkers can provide information on prognosis and enable early treatment.


Subject(s)
Biomarkers , COVID-19 , Cytokines/blood , Biomarkers/blood , COVID-19/diagnosis , Chemokine CXCL10 , Chemokines/blood , Child , Fibrin Fibrinogen Degradation Products , Humans , Interleukin-12 , Interleukin-1beta , Prognosis , SARS-CoV-2 , Severity of Illness Index
4.
[Unspecified Source]; 2020.
Non-conventional in English | [Unspecified Source] | ID: grc-750664
5.
Pediatr Int ; 63(3): 331-337, 2021 Mar.
Article in English | MEDLINE | ID: covidwho-1112281

ABSTRACT

BACKGROUND: Since the COVID-19 pandemic became a serious health concern globally, patients with chronic diseases have required close attention with regard to general risks and individual treatment. We aimed to reveal the general health status of pediatric asthmatic patients during the pandemic, considering the role of household factors in parental attitudes. METHODS: We asked 60 asthmatic patients and their parents to respond to a questionnaire, with the aim of revealing the current health status of the patients and the general approach of the family to asthma management during the pandemic. RESULTS: A total of eight patients had had an asthma attack during the outbreak, but there was no confirmed correlation with COVID-19 infection. Most of the parents had never considered stopping their children's current medications. However, the majority of them reported concerns about the failure of the ambulatory care services and almost all saw their children as being at high risk for COVID-19 infection. There was no significant relationship between these concerns and their psychological status (P > 0.05). CONCLUSIONS: The crucial point regarding asthma management is to control patients' medical and psychological status to minimize the effects of the pandemic. Healthcare professionals should also pay attention to members of the patients' households because their adaptation to the "new normal" of pandemic may directly affect the patients' state of health.


Subject(s)
Asthma/epidemiology , Asthma/therapy , COVID-19/epidemiology , Health Status , Adolescent , Anxiety/epidemiology , Attitude to Health , Child , Child, Preschool , Female , Health Personnel , Histamine Antagonists/therapeutic use , Humans , Male , Pandemics , Parents/psychology , SARS-CoV-2 , Surveys and Questionnaires
6.
Pediatr Int ; 63(7): 797-805, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-944781

ABSTRACT

BACKGROUND: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused a serious epidemic in our country and all over the world since December 2019 and has become a global health problem. The disease caused by the SARS-CoV-2 virus has been named as coronavirus disease 19 (COVID-19). METHODS: We report on the epidemiological and clinical features of 37 children diagnosed with COVID-19. RESULTS: The median age was of the children was 10 years and 57.1% were male. In addition, 78.3% of the children had a history of contact with adult patients who had been diagnosed with COVID-19, and 27.0% had coexisting medical conditions. We found that 40.5% of our patients had mild infection, while 32.4% had moderate infection, and 27.1% had developed severe or critical illness. The most common abnormal laboratory findings in our patients were decreased lymphocytes (45.9%) and increased D-dimer values (43.2%), while abnormal radiological findings were detected in 56.7% of the children. In addition, 64.8% of the children had received azithromycin, 59.4% had received oseltamivir, and hydroxychloroquine was used in combination with azithromycin in 35.1% of the children. Non-invasive mechanical ventilation was required in 27.0% of the children. CONCLUSIONS: Although COVID-19 infection is usually mild in children, severe illness can be seen in children with comorbidities, or even in children who were previously healthy.


Subject(s)
COVID-19/diagnosis , COVID-19/epidemiology , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Pandemics , SARS-CoV-2 , Systemic Inflammatory Response Syndrome , Turkey/epidemiology
7.
Turk Pediatri Ars ; 55(2): 85, 2020.
Article in English | MEDLINE | ID: covidwho-663526
SELECTION OF CITATIONS
SEARCH DETAIL